Clinical Trials Directory

Trials / Completed

CompletedNCT02245542

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Status
Completed
Phase
Study type
Observational
Enrollment
5,775 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia

Conditions

Interventions

TypeNameDescription
DRUGALNA®OCAS®

Timeline

Start date
2005-04-01
Primary completion
2006-02-01
First posted
2014-09-19
Last updated
2014-09-19

Source: ClinicalTrials.gov record NCT02245542. Inclusion in this directory is not an endorsement.